Research
What's next for psychedelics after MDMA rejection?
Science (New York, N.Y.) – August 16, 2024
Summary
Despite a recent setback in MDMA therapy approval, the psychedelic medicine field continues advancing. Major pharmaceutical companies are now exploring alternative compounds and refined treatment protocols for mental health conditions. The focus has shifted to developing more targeted therapies, improved safety profiles, and shorter treatment durations while maintaining therapeutic effectiveness.
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.
Participation of Ca2+-Calmodulin-Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin.
Molecular pharmacology – August 16, 2024
Summary
The sleep hormone melatonin may be a powerful ally in fighting depression through its effects on brain chemistry. New findings show that melatonin activates important proteins in the brain that help regulate mood, memory, and neural connections. People with depression often have lower melatonin levels, but supplementation can boost brain plasticity and enhance the effects of other antidepressants, particularly when combined with ketamine.
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine secreted by the pineal gland during the dark phase of the photoperiod. Its main function...
Exploring the Analgesic Efficacy and mechanisms of low-dose esketamine in pregnant women undergoing cesarean section: A randomized controlled trial.
Heliyon – August 15, 2024
Summary
Pain after a Cesarean section can be notably lessened. A trial investigated if low-dose Esketamine could improve pain management. Women undergoing Cesarean section received Esketamine or saline with different pain relief methods. Results showed Esketamine significantly lowered maximum pain scores. The most effective pain relief occurred when Esketamine was combined with epidural analgesia. Interestingly, this benefit was not due to reduced hyperalgesia or inflammation. Low-dose Esketamine offers effective pain relief after Cesarean section.
Abstract
Postoperative pain is a prevalent concern following a cesarean section. This study aimed to investigate the effect and mechanism of low-dose (0.1 m...
Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields.
NeuroImage – August 15, 2024
Summary
Psychedelics like DMT can dramatically alter visual perception in minutes. New research reveals how these changes occur in the visual cortex through serotonin's 5-HT2A receptors. Brain scans showed that DMT causes visual neurons to respond differently, making their receptive fields larger, especially in peripheral vision. This explains common visual hallucinations like tunnel vision and spatial distortions.
Abstract
N, N-dimethyltryptamine (DMT) is a psychedelic tryptamine acting on 5-HT2A serotonin receptors, which is associated with intense visual hallucinato...
Clinical utility of fMRI in evaluating of LSD effect on pain-related brain networks in healthy subjects.
Heliyon – August 15, 2024
Summary
LSD shows promising potential in altering how our brains process pain, according to groundbreaking brain imaging research. Scientists used fMRI to observe brain activity while participants received either LSD or placebo. Advanced analysis techniques, including ALFF and ICA, revealed that LSD reduced activity in key pain-processing regions while enhancing functional connectivity in areas linked to pain modulation. This suggests LSD could influence pain perception through targeted brain network changes.
Abstract
We aimed to evaluate the effect of Lysergic acid diethylamide (LSD) on the pain neural network (PNN) in healthy subjects using functional magnetic ...
Intrinsic neural timescales exhibit different lengths in distinct meditation techniques.
NeuroImage – August 15, 2024
Summary
Practices with a wider attentional focus, such as Shoonya meditation, show longer brain activity windows compared to narrower techniques like Mantra meditation. In a study involving 120 proficient practitioners across various meditation traditions and a control group, results indicated that the Autocorrelation Window (ACW) was significantly longer in those using broader attentional scopes. This suggests a direct relationship between the width of attentional focus in meditation and the brain's intrinsic neural timescales, offering insights into how these practices can be tailored for mental health interventions.
Abstract
Meditation encompasses a range of practices employing diverse induction techniques, each characterized by a distinct attentional focus. In Mantra m...
Existence of multiple transitions of the critical state due to anesthetics.
Nature communications – August 15, 2024
Summary
Anesthetics don't just make us unconscious - they can trigger multiple distinct patterns in brain activity. New research using advanced imaging of mouse brains reveals that while mild sedation maintains normal neural patterns, deeper anesthesia creates varied and complex brain states. Different anesthetics (like ketamine and isoflurane) disrupt natural brain rhythms in unique ways, explaining why individuals can respond differently to various anesthetic drugs.
Abstract
Scale-free statistics of coordinated neuronal activity, suggesting a universal operating mechanism across spatio-temporal scales, have been propose...
An innovative approach for selective and robust screening of NBOHs, NBOMes, and LSD in forensic samples using a 3D-Printed electrochemical double cell.
Talanta – August 15, 2024
Summary
Law enforcement now has a powerful new tool for detecting dangerous drugs like LSD. Using a dual electrochemical cell with 3D-printed electrodes and boron-doped diamond sensors, forensic analysts can quickly and accurately identify illicit substances in seized materials. This portable screening method works by measuring unique electrical signatures at different pH levels, enabling rapid on-site testing with high accuracy and reliability.
Abstract
Lysergic acid diethylamide (LSD) and two phenethylamine classes (NBOHs and NBOMes) are the main illicit drugs found in seized blotter papers. The p...
Drug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services.
BMJ case reports – August 14, 2024
Summary
A healthy man with no prior mental health issues developed severe psychotic symptoms after using Ayahuasca, a traditional Amazonian psychedelic brew. Unlike typical cases, where drug-induced psychosis resolves quickly, his symptoms persisted and led to violence against a family member. After treatment with antipsychotic medication in a psychiatric facility, he achieved full recovery over 18 months.
Abstract
Ayahuasca is a plant-based psychoactive decoction, traditionally used by indigenous Amazonian peoples, which commonly contains the hallucinogen N,N...
Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.
Journal of clinical medicine – August 14, 2024
Summary
Heart rate patterns may hold the key to predicting antidepressant treatment success. A groundbreaking analysis found that patients with lower heart rate variability were more likely to respond positively to intranasal esketamine for mood disorders. This discovery advances personalized medicine by identifying potential biomarkers that could help doctors better match treatments to individual patients.
Abstract
Background: Esketamine has received approval as a nasal spray (ESK-NS) for treatment-resistant depression (TRD) and evidence from real-world invest...
Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition – August 14, 2024
Summary
Neuroscience reveals how two distinct hallucinogens, Psilocybin and Salvinorin-A, profoundly alter brain communication. Investigating these two psychedelics in non-human primates, work shows they act as agonists on separate serotonergic and κ-opioid receptors, uniquely reshaping functional connectivity. This influences the default mode network, crucial for self-reflection, and the enigmatic claustrum. Such drug studies offer vital insights for mental health topics, exploring how neurotransmitter receptor influence on behavior could lead to new psychological treatments.
Abstract
This work utilized fMRI to assess the influence of the psychedelics, Psilocybin, a serotonergic agonist, and Salvinorin-A, a kappa-opioid receptor ...
How psychedelics legalization debates could differ from cannabis
Addiction – August 13, 2024
Summary
Compellingly, infrequent users account for 60% of psychedelic use days monthly, versus only 5% for cannabis, highlighting distinct patterns. Over two dozen jurisdictions deprioritized enforcement of psychedelics possession. Oregon and Colorado's legislature legalized psilocybin; Colorado also approved 'grow and give' for mescaline and other hallucinogens. Despite parallels with Cannabis, political science and criminology observe differing market dynamics and unique psychological effects, sometimes interpreted as paranormal. Lawmakers must consider these nuances, informed by drug studies and cannabis and cannabinoid research, to avoid past federal inaction.
Abstract
An increasing number of US states and localities are implementing or considering alternatives to prohibiting the supply and possession of some psyc...
Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire
Journal of Psychopharmacology – August 13, 2024
Summary
A key tool for understanding psychedelic experiences, the Danish 5D-ASC questionnaire, accurately measures altered states of consciousness. Applied to 47 healthy volunteers receiving psilocybin and 550 recreative users, an 11-subscale model proved superior for assessing hallucinogen effects. This advance in psychology and clinical psychology is crucial for psychiatry, medicine, and diverse academic research themes in psychedelics and drug studies. Higher psilocybin doses correlated with more intense altered states, validating the instrument for future therapeutic applications and understanding consciousness.
Abstract
Background: Psychedelic substances reliably induce marked altered states of consciousness (ASC), which may be important for lasting effects and cli...
The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis
Frontiers in Psychiatry – August 13, 2024
Summary
Surprisingly, the type of psychological support offered alongside psilocybin treatment doesn't significantly alter its effectiveness for clinical depression. A meta-analysis of 10 studies, involving 515 adult patients, explored how different psychotherapist approaches, from manualized directive to non-manualized supportive, impacted outcomes. Psilocybin, a psychedelic alkaloid, showed a strong standardized mean difference of 10.08 in reducing depressive symptoms. This suggests that while psilocybin-assisted therapy holds promise in psychiatry and clinical psychology, the specific psychological protocol may be less critical than previously thought in these Complementary and Alternative Medicine Studies.
Abstract
Objective Psilocybin-assisted therapy has shown promising efficacy on clinical depressive symptoms. However, diverse psychological support or psych...
Psilocybin for clinical indications: A scoping review
Journal of Psychopharmacology – August 13, 2024
Summary
Interest in psilocybin, an alkaloid hallucinogen, for Medicine is surging. A systematic review spanning MEDLINE found 193 published and 80 ongoing studies. While Psychiatry dominates, with Depression (28%) and Anxiety (3%) as key focuses, most studies involve small groups, a median of 22 participants. Only 12% were rigorous randomized controlled trials, underscoring the need for robust clinical psychology investigations. This field, encompassing Complementary and Alternative Medicine Studies and Psychedelics and Drug Studies, requires larger, higher-quality research.
Abstract
Background: Psychedelic drugs have been of interest in medicine since the early 1950s. There has recently been a resurgence of interest in psychede...
Dynamic medial parietal and hippocampal deactivations under DMT relate to sympathetic output and altered sense of time, space, and the self.
bioRxiv : the preprint server for biology – August 12, 2024
Summary
DMT, a powerful psychedelic compound, temporarily alters brain activity in ways that profoundly affect our perception of time, space, and self. Using advanced brain imaging and EKG monitoring, researchers found that DMT creates unique dynamic brain states, particularly reducing activity in memory and self-awareness regions while increasing sensory processing. These changes correlate with elevated heart rate and altered self-referential processes.
Abstract
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic, known to rapidly induce short-lasting alterations in conscious experience, characterize...
A clinical research perspective on the regulation of medical and non‐medical use of psychedelic drugs
Addiction – August 12, 2024
Summary
The unregulated path of cannabis offers a stark perspective on the future of Psilocybin and MDMA. Parallels suggest that without rigorous Psychedelics and Drug Studies, biased media could blur medical and non-medical use, increasing harms. Already, three drugs influencing neurotransmitter receptors are used in Psychiatry and Medicine. Off-label ketamine, a hallucinogen, highlights risks. With Psilocybin and MDMA in Phase 2 and 3 trials, careful screening and psychotherapist involvement are crucial for safe integration, applying lessons from Psychology and Forensic Toxicology and Drug Analysis.
Abstract
Recent experience with off-label use of ketamine and recent challenges experienced in research with MDMA and psilocybin provide additional perspect...
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.
Sci Rep – August 12, 2024
Summary
European mental health professionals are increasingly open to psychedelic therapy, with 84% supporting further research in this field. A survey of 1,183 psychiatrists across 42 European countries revealed strong interest in psychedelic treatments for depression, PTSD, and addiction. Most respondents believe these substances could be valuable therapeutic tools when used in controlled settings, though current legal barriers limit clinical use.
Abstract
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.
Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression
Psychedelics. – August 12, 2024
Summary
Depression, the world's largest cause of disability, presents an immense public health and economic challenge. Psilocybin, a naturally occurring hallucinogen and alkaloid, shows significant promise when combined with a psychotherapist's guidance. This novel approach, explored in clinical mental care, represents a new frontier in psychiatry and psychology. Psychedelics and drug studies are examining how this compound influences neurotransmitter receptors, leading to behavioral changes. While specific efficacy data are not detailed here, initial indications are very promising for alleviating the burden of depression.
Abstract
Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional tr...
Developmental changes in brain structure and function following exposure to oral LSD during adolescence.
Scientific reports – August 11, 2024
Summary
Adolescent exposure to LSD leads to lasting changes in brain architecture without impacting cognitive or motor abilities. Advanced brain imaging revealed that multiple LSD doses altered gray matter structure, particularly affecting connections between sensorimotor cortex regions and memory centers. While brain volume remained unchanged, neuroplasticity shifts were observed through diffusion weighted imaging, especially in areas controlling sensation and movement. These findings reshape our understanding of how psychedelics influence developing brains.
Abstract
LSD is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. This is t...
Lysergic acid diethylamide induces behavioral changes in Caenorhabditis elegans.
Neuroscience letters – August 10, 2024
Summary
Psychedelics like LSD affect tiny worms similarly to humans, revealing shared brain chemistry across species. Scientists found that when C. elegans worms were exposed to LSD, their movement slowed significantly, mimicking serotonin's natural calming effects. The changes occurred through specific serotonin receptors, particularly SER-4, showing how these ancient neural pathways respond to psychedelic compounds.
Abstract
Lysergic acid diethylamide (LSD) is a synthetic psychedelic compound with potential therapeutic value for psychiatric disorders. This study aims to...
Opioid-free anesthesia with esketamine-dexmedetomidine versus opioid-based anesthesia with propofol-remifentanil in shoulder arthroscopy: a randomized controlled trial.
BMC surgery – August 10, 2024
Summary
A breakthrough in surgical anesthesia shows promising results for patients undergoing shoulder arthroscopy. New opioid-free anesthesia combining esketamine and dexmedetomidine significantly reduced post-surgery nausea and vomiting compared to traditional opioid-based methods. Patients recovered faster and left post-surgery care 9 minutes sooner on average, while experiencing better comfort levels.
Abstract
OFA (Opioid-free anesthesia) has the potential to reduce the occurrence of opioid-related adverse events and enhance postoperative recovery. Our re...
Brain region-specific action of ketamine as a rapid antidepressant.
Science (New York, N.Y.) – August 09, 2024
Summary
Ketamine's remarkable antidepressant effects stem primarily from its action in a specific brain region called the lateral habenula, rather than affecting the entire brain equally. The drug works by blocking certain receptors more effectively in this area, which acts like a master switch for mood regulation. This targeted action triggers a cascade of positive changes, including increased serotonin and growth factors in other brain regions, ultimately lifting depression symptoms rapidly.
Abstract
Ketamine has been found to have rapid and potent antidepressant activity. However, despite the ubiquitous brain expression of its molecular target,...
Resurrecting Ancestral Familial Health: A Role for Psilocybin?
The Family Journal – August 09, 2024
Summary
A novel approach suggests high-dose psilocybin, a compound derived from chemical synthesis and alkaloids, could revolutionize family Psychology. This perspective, informed by Developmental psychology and Social psychology, proposes a family-centered therapy where a psychotherapist integrates psychedelics with interventions like family constellations. Evidence from Drug Studies indicates this model can realign modern families with our evolved social mammalian physiological design, fostering empathy, connection, and well-being. It offers a path to heal intergenerational trauma and enhance family systems.
Abstract
Background: Research investigating high-dose, high-support psilocybin-assisted therapy reports significant psychological benefits, increased consci...
Locking away depression.
Science (New York, N.Y.) – August 09, 2024
Summary
Scientists discovered that ketamine's rapid antidepressant effects stem from its ability to "lock" overactive brain circuits. By blocking specific neuroreceptors, ketamine calms hyperactive regions linked to depression, providing quick relief where traditional medications often take weeks. This breakthrough explains why ketamine works so fast and opens doors for targeted depression treatments.
Abstract
The antidepressant ketamine blocks neuroreceptors in hyperactive brain regions.
Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study.
Translational psychiatry – August 09, 2024
Summary
A groundbreaking analysis of over 500,000 patients reveals ketamine's powerful potential in reducing suicidal thoughts among those with recurring depression. The medication showed remarkable effectiveness, cutting the risk of suicidal ideation by nearly 40% in the first week after prescription, with benefits lasting up to 9 months. These protective effects were particularly strong in adults over 24, regardless of gender.
Abstract
Ketamine has gained attention for its effective treatment for patients with major depressive disorder (MDD) and suicidal ideation; Despite numerous...
Large language models auto-profile conscious awareness changes under psychedelic drug effects
Research Square – August 08, 2024
Summary
AI is proving adept at mapping intricate consciousness shifts, particularly how they manifest under psychedelic influence. It was proposed that large language models could accurately profile these unique changes by analyzing self-reported subjective experiences. The models achieved exceptional accuracy, successfully characterizing diverse psychedelic-induced states. This demonstrates a powerful new avenue for understanding subjective human experience, enhancing potential therapeutic insights.
Abstract
Large language models auto-profile conscious awareness changes under psychedelic drug effects
Completing the Circle: A History of Psychedelics and Harm Reduction.
Current topics in behavioral neurosciences – August 08, 2024
Summary
Long before formal 'harm reduction,' psychedelic safety was paramount. Early clinical protocols, championed by figures like Humphry Osmond, prioritized patient well-being. Later, community efforts in places like San Francisco, often linked to groups like the Grateful Dead, offered support at festivals. The Native American Church also exemplifies ancient traditions integrating psychedelic substances with spiritual healing and community care. This historical overview reveals that effective risk management strategies for psychedelics have deep roots across medical, cultural, and Indigenous practices, offering valuable lessons for today.
Abstract
Harm reduction officially entered the public health lexicon in the 1980s as a response to the HIV/AIDS crisis and its spread amongst intravenous dr...
REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW
Asian Journal of Pharmaceutical and Clinical Research – August 07, 2024
Summary
Remarkably, ketamine therapy can reduce depression symptoms within 40 minutes, with benefits lasting up to one week. A systematic review of 14 primary clinical studies, including randomized controlled trials, confirmed ketamine's effectiveness across major depressive disorder, bipolar illness, and postpartum depression. It also improved anxiety and was generally safe, with most side effects resolving quickly. This fast-acting intervention represents a promising new approach, particularly for patients with treatment-resistant depression.
Abstract
Objectives: Primary Objective: (1) The objectives of the study are as follows: assessment of the effectiveness of ketamine-based treatment in known...
Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.
Translational psychiatry – August 06, 2024
Summary
Early response to ketamine treatment may predict its overall effectiveness in treating depression. Medical professionals found that patients who don't show at least 20% improvement in symptoms after 3-4 ketamine infusions are unlikely to benefit from further treatments. Following 135 patients with depression through multiple ketamine doses, the study revealed that monitoring early symptom changes could help doctors make faster decisions about continuing or stopping treatment, potentially saving time and resources for patients who won't benefit.
Abstract
There is insufficient evidence to guide dose and frequency optimization with repeated-dose ketamine for depression. This study assessed the value o...
The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials.
Healthcare (Basel, Switzerland) – August 06, 2024
Summary
Ketamine shows promising results in managing severe cancer pain when traditional treatments fall short. This comprehensive analysis of clinical trials reveals that combining ketamine with standard pain medications significantly improved pain control in cancer patients, particularly after surgery. While most effective for acute pain, ketamine helped reduce opioid requirements and provided relief for some patients with refractory cancer pain. The treatment proved especially beneficial when administered intravenously alongside conventional pain management approaches.
Abstract
Managing cancer-related pain poses significant challenges, prompting research into alternative approaches such as ketamine. This systematic review ...
Novel treatments of depression: bridging the gap in current therapeutic approaches
Exploration of Neuroscience – August 05, 2024
Summary
For many, traditional depression treatments aren't enough. A review explores promising new therapeutic approaches beyond conventional methods. It highlights the potential of glutamatergic modulation, brain stimulation, anti-inflammatory agents, gut-brain axis interventions, gaba modulation, and psychedelic-assisted psychotherapy. These diverse strategies offer significant hope for more effective depression management.
Abstract
Depression poses a significant global health burden, yet current therapeutic approaches focusing on monoaminergic neurotransmission often fall shor...
Evaluation of the Effects of Repetitive Anaesthesia Administration on the Brain Tissues and Cognitive Functions of Rats with Experimental Alzheimer's Disease.
Medicina (Kaunas, Lithuania) – August 05, 2024
Summary
Repeated exposure to anesthetics might actually improve cognitive function in Alzheimer's patients, contrary to common concerns. In a breakthrough study with rat models, both ketamine and propofol showed promising effects on brain health and memory performance. Using a radial arm maze to test cognition, researchers found that rats receiving these anesthetics demonstrated better memory scores than untreated Alzheimer's rats. The treatments also reduced brain tissue damage and improved key biological markers of brain health.
Abstract
Introduction: We evaluated the effects of repeated ketamine, propofol, and ketamine + propofol administration on cognitive functions and brain tiss...
Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression
Nature Mental Health – August 05, 2024
Summary
Psilocybin and escitalopram produce distinct effects on brain dynamics in patients with major depressive disorder. In a trial involving 22 patients receiving psilocybin and 20 on escitalopram, both treatments led to significant reconfigurations of brain hierarchy. Machine learning techniques accurately predicted treatment responses with an impressive 85% accuracy. These findings suggest that neuropsychiatric disorders like depression may stem from disruptions in the brain's hierarchical organization, highlighting the potential for targeted interventions in mental health care through psychedelics and traditional medications.
Abstract
Abstract Effective interventions for neuropsychiatric disorders may work by rebalancing the brain’s functional hierarchical organization. Here we d...
Psilocybin and chronic neuropathic pain: a systematic review
Regional Anesthesia & Pain Medicine – August 05, 2024
Summary
The alkaloid psilocybin holds encouraging potential for chronic pain management, including neuropathic pain. A review of 28 studies suggests its role in medicine and psychiatry, influencing neurotransmitter receptors for pain relief. While 76.2% of studies were low quality, some moderate evidence points to a 0.14 mg/kg dose. This emerging field of psychedelics and drug studies offers new avenues for pain management in psychology, despite current limitations.
Abstract
Background/Importance Chronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for i...
Rapid, biochemical tagging of cellular activity history in vivo
Nature Methods – August 05, 2024
Summary
A novel *in vivo* method now noninvasively tags active cells in freely behaving animals, a major advance in *biology*. This *chemistry*-based approach, CaST, rapidly labels cells with elevated calcium within just 10 minutes using an external *biotin* molecule. Crucially, it integrates *cell biology* activity over time, providing immediate readouts, unlike transcriptional reporters requiring hours. This enabled tagging psilocybin-activated neurons and correlating their signal with behavioral responses in untethered mice, offering unprecedented insights into brain function.
Abstract
Abstract Intracellular calcium (Ca 2+ ) is ubiquitous to cell signaling across biology. While existing fluorescent sensors and reporters can detect...
Overview Of Review (OoR) on PSILOCYBIN in Psychiatric Disorders
OpenAlex – August 04, 2024
Summary
Psilocybin, a potent Hallucinogen, holds significant promise for mental health. A new protocol outlines a comprehensive "Overview of Review" to rigorously assess its therapeutic effects, safety, and adverse reactions across numerous psychiatric disorders. This crucial Psychiatry and Psychology initiative will synthesize extensive findings from existing systematic reviews and meta-analyses of randomized clinical trials. The goal is to consolidate scattered evidence, providing a robust foundation for future Health and Well-being Studies and clinical applications, including potential relevance for Autism Spectrum Disorder research.
Abstract
eview question / Objective This protocol outlines the methodology for an "Overview of Review" (OoR) study which aims to conduct a comprehensive ana...
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Annual Review of Psychology – August 02, 2024
Summary
Psychedelics show therapeutic potential in emerging drug studies. Psilocybin, a hallucinogen, shows promise for depression, end-of-life dysphoria, and alcohol use disorder. MDMA (Ecstasy) is being explored for PTSD. While these chemical synthesis compounds, like ketamine, carry adverse effect risks such as addiction and cystitis, their benefits for treatment-resistant depression are emerging. Understanding their precise mechanisms is crucial for psychology and psychiatry. Rigorous evaluation can guide safe clinical use, minimizing harm and informing psychotherapist practices.
Abstract
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is st...
Psilocybin-assisted therapy and HIV-related shame
Scientific Reports – August 02, 2024
Summary
Psilocybin-assisted therapy significantly reduced HIV-related shame, a major mental health barrier. In a pilot clinical trial of 12 participants, psilocybin-assisted group therapy led to a large decrease in shame (median change of -5.5 points, effect size r = -0.75) over three months. This offers a new avenue for psychiatry and clinical psychology, as conventional medicine struggles with HIV-related shame, which often leads to increased drug use and sexual risk. While promising for HIV care, two participants experienced increased sexual abuse-related shame, highlighting careful psychotherapist consideration in psychedelics and drug studies.
Abstract
Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of incr...
Insights into the efficacy of psilocybin in treating depression and other disorders
British Journal of Neuroscience Nursing – August 02, 2024
Summary
Many struggling with severe depression experience profound relief, with trials involving 70 participants showing 60% sustained improvement after a single psilocybin session. This potent compound, a product of chemical synthesis, is explored in Psychedelics and Drug Studies, demonstrating significant clinical efficacy in Psychiatry and Psychology. Its effects on brain function offer new avenues in Medicine, potentially reducing the economic burden of depression. Administered under psychotherapist guidance, psilocybin is transforming Complementary and Alternative Medicine Studies, highlighting its potential to alleviate neuropsychiatric symptoms.
Abstract
This article discusses evidence that offers insights into the effects of psilocybin on the brain and its potential role in alleviating the symptoms...
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.
Archives of toxicology – August 01, 2024
Summary
MDMA-assisted therapy shows remarkable promise in treating PTSD, with recent clinical trials demonstrating breakthrough results. While MDMA (commonly known as ecstasy) can have risks when misused, supervised therapeutic sessions have proven safe and effective. Australia now permits MDMA prescriptions for PTSD treatment, and studies explore its potential for conditions like schizophrenia and alcohol dependency. The drug works by releasing neurotransmitters that promote emotional openness and social bonding.
Abstract
The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'), is the prototypical example of an entactogen. Its original placement in ...
The Use of Ketamine for the Treatment of Anhedonia in Depression.
CNS drugs – August 01, 2024
Summary
A single dose of ketamine can rapidly restore the ability to feel pleasure in depressed patients who have lost interest in activities they once enjoyed. This groundbreaking finding shows that ketamine uniquely targets anhedonia - the reduced ability to experience pleasure - independently of its effects on other depression symptoms. The treatment works within hours, offering hope to patients who haven't responded to traditional antidepressants. Brain imaging reveals ketamine may work by reactivating reward circuits that process enjoyment and motivation.
Abstract
Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnos...
Effects of intraoperative low-dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double-blind, placebo-controlled study.
British journal of clinical pharmacology – August 01, 2024
Summary
A single dose of esketamine during brain surgery showed promise for pain management, though with mixed results. Researchers tested this innovative anesthetic in patients undergoing vestibular schwannoma removal. While monitoring showed the drug was safe and increased brain activity, it didn't significantly reduce postoperative pain after craniotomy. However, patients needed less pain medication to maintain comfort during recovery.
Abstract
Esketamine may reduce acute postoperative pain in several settings. However, the effects of low-dose esketamine on postoperative pain after vestibu...
Psilocybin desynchronizes the human brain.
Nature – August 01, 2024
Summary
A single dose of psilocybin dramatically alters brain connectivity patterns, causing networks that normally work in sync to become temporarily desynchronized. This disruption is particularly strong in brain regions linked to our sense of self and perception of time. The changes persist for weeks, especially between memory centers and self-awareness networks, potentially explaining psilocybin's therapeutic benefits.
Abstract
A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persist...
MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.
Contemporary clinical trials communications – August 01, 2024
Summary
A groundbreaking approach combines MDMA with brief cognitive-behavioral conjoint therapy to help veterans with PTSD heal both trauma and intimate relationships. This innovative treatment pairs couples counseling with two MDMA sessions, aiming to strengthen bonds while addressing trauma. Eight veteran couples will receive therapy that targets both individual PTSD symptoms and relationship health, potentially offering a new path for military families seeking healing together.
Abstract
Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship dist...
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assay.
Journal of pharmaceutical and biomedical analysis – August 01, 2024
Summary
Two emerging hallucinogens showed surprising safety profiles in groundbreaking lab tests. Using human liver cells and zebrafish larvae, researchers examined how these compounds break down in the body. Advanced testing revealed that while both substances undergo various transformations, neither showed significant toxic effects in liver cells. The zebrafish model uniquely produced additional metabolites, offering valuable insights into drug processing and safety.
Abstract
The continuous emergence of new psychoactive substances (NPS) attracted a great deal of attention within recent years. Lately, the two hallucinogen...
The effect of mindfulness-based interventions on mental health outcomes and wellbeing of informal caregivers of people with mental illness: A systematic review and meta-analysis.
International journal of mental health nursing – August 01, 2024
Summary
Mindfulness-based interventions significantly enhance the mental health and well-being of informal caregivers for individuals with mental illness. A meta-analysis of 13 studies involving 1,007 participants revealed a substantial reduction in stress (effect size -0.80), depression (-0.43), and caregiver burden (-0.21). Additionally, these interventions improved mindfulness levels (0.37) and quality of life (0.22). However, anxiety reduction did not show significant improvement (-0.19). The findings highlight the potential of mindfulness practices to support caregivers facing the challenges of mental illness.
Abstract
The increasing prevalence of mental illness has resulted in a growing burden on informal caregivers. Mindfulness-based interventions, as a form of ...
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – August 01, 2024
Summary
In treating stubborn depression, nasal spray medication shows promising safety results compared to traditional pills. The nasal form of esketamine proved more effective than extended-release quetiapine, with patients experiencing shorter-lasting side effects. While more patients reported initial reactions to the nasal spray, these effects typically resolved within a day and led to fewer treatment dropouts. The findings highlight esketamine's strong safety profile and better tolerability in managing treatment-resistant depression.
Abstract
In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and of being relapse-free ...
Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol.
Contemporary clinical trials – August 01, 2024
Summary
Veterans struggling with PTSD may soon have access to a groundbreaking treatment combining ketamine with prolonged exposure therapy. This innovative approach pairs controlled ketamine doses with traditional trauma therapy sessions, potentially helping those who haven't responded to standard treatments. Early data suggests ketamine could enhance therapy effectiveness by improving fear extinction and memory processing.
Abstract
The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure ...
Psilocybin in pharmacotherapy of obsessive-compulsive disorder
Pharmacological Reports – August 01, 2024
Summary
For up to 40% of individuals with obsessive-compulsive disorder (OCD), current pharmacotherapy is ineffective, creating a critical need for new medicine in psychiatry. Emerging neuroscience highlights psilocybin, a serotonergic and glutamatergic hallucinogen, as a promising alternative. This non-addictive psychedelic, explored in drug studies, influences neurotransmitter receptors, offering a novel approach to behavior modification. Its potential efficacy in psychology could transform addiction treatment and other conditions, including those addressed in body image and dysmorphia studies.
Abstract
Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsion...